{
    "info": {
        "nct_id": "NCT04428203",
        "official_title": "A Phase I/Ib Study on the Safety of Epidiolex in Patients With Prostate Cancer With Rising PSA After Localized Therapy With Either Surgery or Radiation",
        "inclusion_criteria": "* Completion of localized therapy (prostatectomy or radiotherapy) for prostate adenocarcinoma (either histologically or cytologically confirmed)\n* Biochemical (PSA) recurrence, defined as: * PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy OR * PSA increase of 2.0 ng/ml above post-therapy nadir after radiotherapy NOTE: PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 2\n* Absolute neutrophil count >= 1,500/microliters (at baseline [pre-study])\n* Platelets >= 80,000/microliters (at baseline [pre-study])\n* Total bilirubin =< institutional upper limit of normal (at baseline [pre-study])\n* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase) =< institutional upper limit of normal (at baseline [pre-study])\n* Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])\n* Patients with a prior or concurrent malignancy (non-prostate) whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen as determined by the treating physician are eligible\n* Given that worsening of an underlying state of mental depression or suicidal ideation has been reported with Epidiolex, patients should be carefully screened for depression at baseline and if there are indications or a history of depression it is strongly recommended that these patients be closely followed together with behavioral health or psychiatric medical support. Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled on this protocol\n* Concurrent use of over-the-counter CBD oil, Marinol or marijuana is not permitted. Patients with a history of current over-the-counter CBD oil, Marinol or marijuana use for any reason are eligible only if they do the following: * Complete a one-week washout period prior to study initiation * Refrain from non-study related CBD oil, Marinol or marijuana use while on-study\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* History of hypersensitivity to Epidiolex (cannabidiol) or sesame seeds (one of the inactive ingredients in Epidiolex)\n* Any radiological evidence of metastatic disease (determined by standard of care computed tomography [CT] scans of abdomen. pelvis, chest, whole body bone scan or Axium positron emission tomography scan). Questionable lesions on bone scan will be confirmed by standard of care methods such as plain X-rays or Axium positron emission tomography scan, if not previously performed\n* Receipt of prior cytotoxic chemotherapy for recurrent prostate cancer\n* Use of androgen deprivation therapy (for example, bicalutamide, flutamide, nilutamide, or leuprolide acetate) concurrently or within the previous 3 months.\n* Uncontrolled intercurrent illness such as active infections. Other illnesses will be evaluated and eligibility status determined at the discretion of the treating physician and the investigator\n* Psychiatric illness/social situations that would limit compliance with study requirements\n* Concomitant use of valproate or clobazam\n* Concurrent use of over-the-counter CBD oil, Marinol or marijuana\n* Epidiolex is a moderate inhibitor of CYP2C19 and a moderate/strong inhibitor of CYP3A4, therefore concurrent use of CYP2C19 substrates is not allowed",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                "criterions": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status =< 2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Given that worsening of an underlying state of mental depression or suicidal ideation has been reported with Epidiolex, patients should be carefully screened for depression at baseline and if there are indications or a history of depression it is strongly recommended that these patients be closely followed together with behavioral health or psychiatric medical support. Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled on this protocol",
                "criterions": [
                    {
                        "exact_snippets": "patients should be carefully screened for depression at baseline",
                        "criterion": "depression",
                        "requirement": {
                            "requirement_type": "screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if there are indications or a history of depression",
                        "criterion": "history of depression",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled",
                        "criterion": "established diagnosis of depression",
                        "requirement": {
                            "requirement_type": "diagnosis",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled",
                        "criterion": "established diagnosis of depression",
                        "requirement": {
                            "requirement_type": "risk assessment for Epidiolex administration",
                            "expected_value": "not hazardous"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "patients should be carefully screened for depression at baseline",
                        "criterion": "depression",
                        "requirement": {
                            "requirement_type": "screening",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "if there are indications or a history of depression",
                        "criterion": "history of depression",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled",
                                "criterion": "established diagnosis of depression",
                                "requirement": {
                                    "requirement_type": "diagnosis",
                                    "expected_value": false
                                }
                            },
                            {
                                "exact_snippets": "Patients with an established diagnosis of depression that, in the assessment of the investigator may make the administration of Epidiolex hazardous, should not be enrolled",
                                "criterion": "established diagnosis of depression",
                                "requirement": {
                                    "requirement_type": "risk assessment for Epidiolex administration",
                                    "expected_value": "not hazardous"
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent use of over-the-counter CBD oil, Marinol or marijuana is not permitted. Patients with a history of current over-the-counter CBD oil, Marinol or marijuana use for any reason are eligible only if they do the following: * Complete a one-week washout period prior to study initiation * Refrain from non-study related CBD oil, Marinol or marijuana use while on-study",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana is not permitted.",
                        "criterion": "concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Patients with a history of current over-the-counter CBD oil, Marinol or marijuana use for any reason are eligible only if they do the following: * Complete a one-week washout period prior to study initiation",
                        "criterion": "history of current over-the-counter CBD oil, Marinol or marijuana use",
                        "requirement": {
                            "requirement_type": "washout period",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Refrain from non-study related CBD oil, Marinol or marijuana use while on-study",
                        "criterion": "non-study related CBD oil, Marinol or marijuana use while on-study",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana is not permitted.",
                        "criterion": "concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Patients with a history of current over-the-counter CBD oil, Marinol or marijuana use for any reason are eligible only if they do the following: * Complete a one-week washout period prior to study initiation",
                                "criterion": "history of current over-the-counter CBD oil, Marinol or marijuana use",
                                "requirement": {
                                    "requirement_type": "washout period",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "week"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "Refrain from non-study related CBD oil, Marinol or marijuana use while on-study",
                                "criterion": "non-study related CBD oil, Marinol or marijuana use while on-study",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Total bilirubin =< institutional upper limit of normal (at baseline [pre-study])",
                "criterions": [
                    {
                        "exact_snippets": "Total bilirubin =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Total bilirubin =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must be MALE",
                "criterions": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be MALE",
                        "criterion": "sex",
                        "requirement": {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Biochemical (PSA) recurrence, defined as: * PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy OR * PSA increase of 2.0 ng/ml above post-therapy nadir after radiotherapy NOTE: PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                "criterions": [
                    {
                        "exact_snippets": "PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy",
                        "criterion": "PSA level after radical prostatectomy",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 0.2,
                                "unit": "ng/ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy",
                        "criterion": "PSA level after radical prostatectomy",
                        "requirement": {
                            "requirement_type": "increase_above_nadir",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "PSA increase of 2.0 ng/ml above post-therapy nadir after radiotherapy",
                        "criterion": "PSA increase after radiotherapy",
                        "requirement": {
                            "requirement_type": "increase_above_nadir",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2.0,
                                "unit": "ng/ml"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                        "criterion": "PSA measurement timing",
                        "requirement": {
                            "requirement_type": "number_of_measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "time points"
                            }
                        }
                    },
                    {
                        "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                        "criterion": "PSA measurement timing",
                        "requirement": {
                            "requirement_type": "interval_between_measurements",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy",
                                "criterion": "PSA level after radical prostatectomy",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 0.2,
                                        "unit": "ng/ml"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA of >= 0.2 ng/ml that has increased above nadir following radical prostatectomy",
                                "criterion": "PSA level after radical prostatectomy",
                                "requirement": {
                                    "requirement_type": "increase_above_nadir",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                                "criterion": "PSA measurement timing",
                                "requirement": {
                                    "requirement_type": "number_of_measurements",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "time points"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                                "criterion": "PSA measurement timing",
                                "requirement": {
                                    "requirement_type": "interval_between_measurements",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "PSA increase of 2.0 ng/ml above post-therapy nadir after radiotherapy",
                                "criterion": "PSA increase after radiotherapy",
                                "requirement": {
                                    "requirement_type": "increase_above_nadir",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2.0,
                                        "unit": "ng/ml"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                                "criterion": "PSA measurement timing",
                                "requirement": {
                                    "requirement_type": "number_of_measurements",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "time points"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "PSA measured at two consecutive time points (separated by 4 or more weeks) is required in order to demonstrate the requisite increase in PSA",
                                "criterion": "PSA measurement timing",
                                "requirement": {
                                    "requirement_type": "interval_between_measurements",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients with a prior or concurrent malignancy (non-prostate) whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen as determined by the treating physician are eligible",
                "criterions": [
                    {
                        "exact_snippets": "Patients with a prior or concurrent malignancy (non-prostate)",
                        "criterion": "prior or concurrent non-prostate malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen as determined by the treating physician",
                        "criterion": "potential for malignancy or its treatment to interfere with safety or efficacy assessment",
                        "requirement": {
                            "requirement_type": "potential to interfere",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients with a prior or concurrent malignancy (non-prostate)",
                        "criterion": "prior or concurrent non-prostate malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen as determined by the treating physician",
                        "criterion": "potential for malignancy or its treatment to interfere with safety or efficacy assessment",
                        "requirement": {
                            "requirement_type": "potential to interfere",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                "criterions": [
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at baseline [pre-study]"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockcroft-Gault formula"
                        }
                    },
                    {
                        "exact_snippets": "Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2 using the Cockcroft-Gault formula (at baseline [pre-study])",
                        "criterion": "glomerular filtration rate (GFR)",
                        "requirement": {
                            "requirement_type": "timepoint",
                            "expected_value": "at baseline [pre-study]"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Platelets >= 80,000/microliters (at baseline [pre-study])",
                "criterions": [
                    {
                        "exact_snippets": "Platelets >= 80,000/microliters (at baseline [pre-study])",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 80000,
                                "unit": "microliters"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 80,000/microliters (at baseline [pre-study])",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at baseline [pre-study]"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Platelets >= 80,000/microliters (at baseline [pre-study])",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 80000,
                                "unit": "microliters"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelets >= 80,000/microliters (at baseline [pre-study])",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at baseline [pre-study]"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase) =< institutional upper limit of normal (at baseline [pre-study])",
                "criterions": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST)... =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT)... =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Aspartate aminotransferase (AST)... =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "aspartate aminotransferase (AST) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    },
                    {
                        "exact_snippets": "alanine aminotransferase (ALT)... =< institutional upper limit of normal (at baseline [pre-study])",
                        "criterion": "alanine aminotransferase (ALT) level",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional upper limit of normal"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Absolute neutrophil count >= 1,500/microliters (at baseline [pre-study])",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count >= 1,500/microliters (at baseline [pre-study])",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microliters"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count >= 1,500/microliters (at baseline [pre-study])",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microliters"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Ability to understand and the willingness to sign a written informed consent document",
                "criterions": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Receipt of prior cytotoxic chemotherapy for recurrent prostate cancer",
                "criterions": [
                    {
                        "exact_snippets": "Receipt of prior cytotoxic chemotherapy for recurrent prostate cancer",
                        "criterion": "prior cytotoxic chemotherapy for recurrent prostate cancer",
                        "requirement": {
                            "requirement_type": "history of receipt",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "not_criteria": {
                    "exact_snippets": "Receipt of prior cytotoxic chemotherapy for recurrent prostate cancer",
                    "criterion": "prior cytotoxic chemotherapy for recurrent prostate cancer",
                    "requirement": {
                        "requirement_type": "history of receipt",
                        "expected_value": true
                    }
                }
            }
        },
        {
            "identified_line": {
                "line": "* Psychiatric illness/social situations that would limit compliance with study requirements",
                "criterions": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Psychiatric illness ... that would limit compliance with study requirements",
                        "criterion": "psychiatric illness",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "social situations that would limit compliance with study requirements",
                        "criterion": "social situations",
                        "requirement": {
                            "requirement_type": "impact on compliance",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any radiological evidence of metastatic disease (determined by standard of care computed tomography [CT] scans of abdomen. pelvis, chest, whole body bone scan or Axium positron emission tomography scan). Questionable lesions on bone scan will be confirmed by standard of care methods such as plain X-rays or Axium positron emission tomography scan, if not previously performed",
                "criterions": [
                    {
                        "exact_snippets": "Any radiological evidence of metastatic disease (determined by standard of care computed tomography [CT] scans of abdomen. pelvis, chest, whole body bone scan or Axium positron emission tomography scan)",
                        "criterion": "metastatic disease",
                        "requirement": {
                            "requirement_type": "radiological evidence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Questionable lesions on bone scan will be confirmed by standard of care methods such as plain X-rays or Axium positron emission tomography scan, if not previously performed",
                        "criterion": "questionable lesions on bone scan",
                        "requirement": {
                            "requirement_type": "confirmation by standard of care methods",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any radiological evidence of metastatic disease (determined by standard of care computed tomography [CT] scans of abdomen. pelvis, chest, whole body bone scan or Axium positron emission tomography scan)",
                                "criterion": "metastatic disease",
                                "requirement": {
                                    "requirement_type": "radiological evidence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Questionable lesions on bone scan will be confirmed by standard of care methods such as plain X-rays or Axium positron emission tomography scan, if not previously performed",
                                "criterion": "questionable lesions on bone scan",
                                "requirement": {
                                    "requirement_type": "confirmation by standard of care methods",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of hypersensitivity to Epidiolex (cannabidiol) or sesame seeds (one of the inactive ingredients in Epidiolex)",
                "criterions": [
                    {
                        "exact_snippets": "History of hypersensitivity to Epidiolex (cannabidiol)",
                        "criterion": "hypersensitivity to Epidiolex (cannabidiol)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypersensitivity to ... sesame seeds (one of the inactive ingredients in Epidiolex)",
                        "criterion": "hypersensitivity to sesame seeds",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of hypersensitivity to Epidiolex (cannabidiol)",
                        "criterion": "hypersensitivity to Epidiolex (cannabidiol)",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "hypersensitivity to ... sesame seeds (one of the inactive ingredients in Epidiolex)",
                        "criterion": "hypersensitivity to sesame seeds",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of androgen deprivation therapy (for example, bicalutamide, flutamide, nilutamide, or leuprolide acetate) concurrently or within the previous 3 months.",
                "criterions": [
                    {
                        "exact_snippets": "Use of androgen deprivation therapy (for example, bicalutamide, flutamide, nilutamide, or leuprolide acetate) concurrently or within the previous 3 months.",
                        "criterion": "androgen deprivation therapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "concurrent"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Use of androgen deprivation therapy (for example, bicalutamide, flutamide, nilutamide, or leuprolide acetate) concurrently or within the previous 3 months.",
                        "criterion": "androgen deprivation therapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 1,
                                        "unit": "concurrent"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concomitant use of valproate or clobazam",
                "criterions": [
                    {
                        "exact_snippets": "Concomitant use of valproate",
                        "criterion": "valproate use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant use of ... clobazam",
                        "criterion": "clobazam use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concomitant use of valproate",
                        "criterion": "valproate use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concomitant use of ... clobazam",
                        "criterion": "clobazam use",
                        "requirement": {
                            "requirement_type": "concomitant use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled intercurrent illness such as active infections. Other illnesses will be evaluated and eligibility status determined at the discretion of the treating physician and the investigator",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent illness such as active infections",
                        "criterion": "intercurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "active infections",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Uncontrolled intercurrent illness such as active infections",
                        "criterion": "intercurrent illness",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    },
                    {
                        "exact_snippets": "active infections",
                        "criterion": "infection",
                        "requirement": {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Epidiolex is a moderate inhibitor of CYP2C19 and a moderate/strong inhibitor of CYP3A4, therefore concurrent use of CYP2C19 substrates is not allowed",
                "criterions": [
                    {
                        "exact_snippets": "concurrent use of CYP2C19 substrates is not allowed",
                        "criterion": "concurrent use of CYP2C19 substrates",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "concurrent use of CYP2C19 substrates is not allowed",
                        "criterion": "concurrent use of CYP2C19 substrates",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                "criterions": [
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of over-the-counter CBD oil",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of Marinol",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of marijuana",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of over-the-counter CBD oil",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of Marinol",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Concurrent use of over-the-counter CBD oil, Marinol or marijuana",
                        "criterion": "use of marijuana",
                        "requirement": {
                            "requirement_type": "concurrent use",
                            "expected_value": true
                        }
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "* Completion of localized therapy (prostatectomy or radiotherapy) for prostate adenocarcinoma (either histologically or cytologically confirmed)",
                "criterions": [
                    {
                        "exact_snippets": "Completion of localized therapy (prostatectomy or radiotherapy)",
                        "criterion": "localized therapy for prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Completion of localized therapy (prostatectomy or radiotherapy)",
                        "criterion": "localized therapy for prostate adenocarcinoma",
                        "requirement": {
                            "requirement_type": "therapy_type",
                            "expected_value": [
                                "prostatectomy",
                                "radiotherapy"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "prostate adenocarcinoma (either histologically or cytologically confirmed)",
                        "criterion": "prostate adenocarcinoma diagnosis",
                        "requirement": {
                            "requirement_type": "confirmation_method",
                            "expected_value": [
                                "histologically",
                                "cytologically"
                            ]
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}